IBI Ag, a crop protection company developing biological insecticides with reduced environmental impact, has completed a $10 million Series A funding round led by Corteva through its Corteva Catalyst platform.

The investment round included participation from The Trendlines Group, Iron Nation, Consensus Business Group, Bandera Capital, and First Imagine Ventures, along with a grant from the Israel Innovation Authority.

IBI Ag specializes in creating insect control products using single-domain antibodies, a technology adapted from pharmaceutical applications for agricultural use. These biological solutions target both sucking and chewing insects while aiming to protect beneficial species and minimize environmental harm.

“We’re proud to have the continued confidence of our investors and to welcome Bandera Capital and First Imagine Ventures to the IBI Ag family,” said Arnon Heyman, CEO of IBI Ag. “With the completion of our Series A, we are well positioned to bring our novel biological solutions closer to farmers worldwide, supporting both productivity and sustainability.”

The funding will support product development and regulatory processes as the company works toward bringing its pest control solutions to market.

Tom Greene, senior director at Corteva and global leader for Corteva Catalyst, emphasized the partnership’s potential impact: “The collaboration between IBI Ag and Corteva is a clear example of how working together can deliver innovation that increases performance and provides more sustainable solutions in crop protection.”

Corteva’s Catalyst platform focuses on partnering with early-stage companies developing technologies that help farmers increase food production sustainably.

Founded by The Trendlines Group with Dr. Amir Ayali and Dr. Rony Oren Benaroya, IBI Ag is working to provide farmers with new tools for managing crop pests while reducing ecological impact compared to traditional chemical pesticides.